(News Bulletin 247) – The Janssen Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study showed that Carvykti (Cilta-cel) reduced the risk of disease progression or death by 74% versus two standard-of-care treatments in adults with relapsed, lenalidomide-refractory multiple myeloma.
“Cilta-cel has demonstrated a remarkably high level of efficacy in the latest lines of treatment, and these latest data also show its potential in the first lines,” said Binod Dhakal, associate professor and study investigator.
“The results clearly demonstrate the effectiveness of Cilta-cel when administered earlier in a patient’s treatment journey,” said Jordan Schecter, MD, vice president, Janssen Research & Development.
“Carvykti represents an important therapy in our approach to redefining the treatment of multiple myeloma,” said Jordan Schecter, MD, vice president, Janssen.
On May 25, 2023, Janssen submitted a Type II variation application to the European Medicines Agency based on the results of the study for approval of Carvykti for the treatment of patients with relapsed and refractory multiple myeloma. lenalidomide.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
